Urea Breath Testing Market Summary
The global urea breath testing market size was valued at USD 374.1 million in 2025 and is projected to grow from USD 380.6 million in 2026 to USD 515.9 million by 2033, at a CAGR of 4.4% from 2026 to 2033. The North America urea breath testing market held the largest share of 48.4% of the global market in 2025. The market growth is primarily driven by the rising global prevalence of Helicobacter pylori infections and associated gastrointestinal disorders, increasing preference for non-invasive and accurate gastrointestinal diagnostic technologies, and growing focus on gastric cancer prevention, early disease detection, and post-treatment monitoring. In addition, the expanding adoption of point-of-care diagnostic solutions, portable breath analyzers, and advanced 13C and 14C urea breath testing systems is further supporting global market expansion.
Key Market Trends & Insights
- By test location: Hospital-based testing segment led the global urea breath testing industry and accounted for a share of 39.5% in 2025.
- By type: H. pylori initial diagnosis segment led the market and accounted for a share of 39.0% in 2025.
- By patient population: Adults segment led the market and accounted for a share of 65.7% in 2025.
Regional Highlights
- Largest regional market: North America (48.4% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The urea breath testing industry in the U.S. held the largest revenue share in 2025.
Market Size & Forecast
- Market size in 2025: USD 374.1 Million
- Estimated market size in 2026: USD 380.6 Million
- Projected market size by 2033: USD 515.9 Million
- CAGR (2026-2033): 4.4%
Market Dynamics
Drivers - Rising Prevalence of Helicobacter pylori Infections and Gastrointestinal Disorders
The rising global prevalence of Helicobacter pylori (H. pylori) infections and the associated gastrointestinal disorders are the primary drivers of the urea breath test industry. H. pylori is recognized as one of the most common chronic bacterial infections worldwide and is strongly associated with peptic ulcers, chronic gastritis, dyspepsia, and gastric cancer, increasing the demand for accurate and non-invasive diagnostic solutions. According to a global study published in Gastroenterology in April 2024, the global prevalence of H. pylori infection was approximately 43.9% among adults, while infection rates among children and adolescents remained as high as 35.1%. The prevalence is significantly higher in developing countries, reaching nearly 51%, primarily due to poor sanitation, overcrowding, and limited access to healthcare services, thereby accelerating the adoption of urea breath testing worldwide.
The increasing disease burden associated with Helicobacter pylori (H. pylori) infections is driving significant demand for non-invasive diagnostic solutions, such as urea breath tests. According to a study published in Nature Medicine in July 2025, approximately 15.6 million lifetime gastric cancer cases are expected globally among individuals born between 2008 and 2017, with nearly 76% attributable to H. pylori infection. The rising prevalence of peptic ulcers, chronic gastritis, dyspepsia, and gastric cancer is accelerating the adoption of early screening technologies worldwide. Increasing awareness regarding preventive healthcare and population-based H. pylori screening programs is further supporting the growth of the Urea Breath Test Market.
The U.S. National Toxicology Program (NTP) reported that more than half of the global population is infected with Helicobacter pylori (H. pylori). At the same time, the prevalence in the United States ranges between 30% and 36%. The organization also stated that H. pylori infection contributes to nearly 780,000 new cancer cases annually worldwide, accounting for approximately 6.2% of all global cancer cases. Chronic H. pylori infection is strongly associated with peptic ulcers, chronic gastritis, and non-cardia gastric cancer, significantly increasing the demand for early and accurate diagnostic solutions. The rising prevalence of gastrointestinal diseases, combined with increasing awareness regarding preventive healthcare, is substantially accelerating the adoption of urea breath testing across hospitals, gastroenterology clinics, and diagnostic laboratories globally.
Restraint - Limited Awareness and Availability of Alternative Diagnostic Methods
Limited awareness regarding Helicobacter pylori (H. pylori) infections and the widespread availability of alternative diagnostic methods are significant factors restraining the growth of the urea breath test industry. In many low- and middle-income countries, inadequate healthcare infrastructure, limited access to advanced diagnostic facilities, and low awareness regarding early gastrointestinal disease screening continue to hinder the adoption of urea breath testing. A substantial portion of the population in developing regions remains undiagnosed due to insufficient access to gastroenterology services and delayed clinical consultations. In addition, alternative diagnostic approaches such as stool antigen tests, serology-based antibody tests, endoscopy, and biopsy procedures are widely used due to their lower costs and broader accessibility across healthcare settings. Furthermore, the relatively high cost of advanced 13C urea breath test analyzers, limited reimbursement support, and the need for specialized equipment and trained personnel further restrict market penetration, particularly in resource-constrained and rural healthcare environments.
Opportunity - Growing Adoption of Non-Invasive and Point-of-Care Gastrointestinal Diagnostics
The growing adoption of non-invasive, point-of-care diagnostic technologies presents a significant opportunity for the urea breath test industry. Rising awareness regarding early detection of Helicobacter pylori (H. pylori) infections and gastrointestinal disorders is driving demand for rapid, accurate, and patient-friendly diagnostic solutions. Healthcare providers are increasingly shifting toward non-invasive testing methods such as urea breath tests due to their high sensitivity, fast turnaround times, and lower patient discomfort compared to endoscopic procedures. In addition, the expanding utilization of point-of-care testing (POCT) across hospitals, outpatient clinics, and ambulatory diagnostic centers is creating favorable market opportunities.
Growing investments in portable diagnostic analyzers, digital healthcare integration, and automated breath-testing systems are expected to support future market expansion. Emerging economies across Asia-Pacific, Latin America, and the Middle East are witnessing continuous improvements in healthcare infrastructure and diagnostic accessibility, creating strong growth potential for market participants. Furthermore, rising government initiatives focused on gastric cancer prevention and population-based H. pylori screening programs are expected to accelerate further accelerate the adoption of urea breath testing during the forecast period.
Market Concentration & Characteristics
The urea breath test industry demonstrates a moderate to high degree of innovation driven by continuous advancements in non-invasive gastrointestinal diagnostic technologies, portable analyzers, and point-of-care testing solutions. Companies are increasingly developing advanced 13C and 14C urea breath testing systems with improved sensitivity, faster turnaround times, enhanced portability, and digital connectivity to improve diagnostic efficiency across hospitals and diagnostic laboratories. The integration of infrared spectroscopy, isotope ratio mass spectrometry, and automated reporting platforms is further improving workflow optimization and diagnostic accuracy. In 2025, researchers introduced AI-assisted diagnostic systems for Helicobacter pylori detection capable of improving diagnostic efficiency and interpretation accuracy in gastrointestinal screening workflows. Additionally, AI-assisted diagnostics, home-based 13C urea breath testing, portable analyzers, and telehealth-integrated platforms significantly enhanced accessibility, diagnostic efficiency, and adoption of point-of-care gastrointestinal testing, creating substantial opportunities for decentralized healthcare delivery.
The urea breath test industry demonstrates a moderate level of mergers and acquisitions (M&A) activity driven by increasing demand for non-invasive gastrointestinal diagnostics and expanding Helicobacter pylori testing capabilities. Companies are actively pursuing strategic collaborations, technology acquisitions, and partnerships to strengthen diagnostic portfolios and expand point-of-care testing presence. Market participants are increasingly investing in portable breath analyzers, AI-enabled diagnostic platforms, and automated gastrointestinal testing systems to improve diagnostic efficiency and patient accessibility. Furthermore, growing strategic collaborations among gastrointestinal diagnostic providers, hospitals, and breath-testing technology companies are supporting the commercialization of advanced breath-testing solutions. These strategic activities are expected to enhance innovation, geographic expansion, and competitive positioning across the global market.
Regulatory frameworks significantly influence the urea breath test industry by governing diagnostic accuracy, product approvals, patient safety, and radiation exposure standards for 13C and 14C urea breath testing systems. Regulatory agencies such as the U.S. Food and Drug Administration and regional healthcare authorities require stringent clinical validation and quality compliance before commercialization. Increasing regulatory support for non-invasive diagnostics and gastric cancer prevention programs is encouraging the adoption of advanced urea breath testing technologies. However, lengthy approval procedures and varying regional compliance requirements may restrain market expansion to some extent.
The urea breath test industry is experiencing continued growth driven by rising demand for non-invasive Helicobacter pylori diagnostics and point-of-care gastrointestinal testing solutions. Companies are expanding their portfolios by developing advanced 13C and 14C urea breath-testing systems with improved sensitivity, faster turnaround times, enhanced portability, and digital connectivity. In March 2025, researchers at Ulm University developed a miniaturized mobile breath sensor for rapid detection of H. pylori, enabling portable, cost-effective gastrointestinal diagnostics. Furthermore, companies such as Aloft MedTech introduced advanced 13C urea breath analyzers to improve diagnostic efficiency and expand global access to point-of-care testing.
The urea breath test industry is witnessing regional expansion driven by the rising prevalence of Helicobacter pylori infections, increasing gastrointestinal disease awareness, and improving healthcare infrastructure across emerging economies. Asia-Pacific is experiencing strong growth driven by large patient populations and expanding access to non-invasive diagnostics in China, India, and Japan. North America and Europe continue to expand through the adoption of advanced diagnostic technologies and point-of-care testing. Additionally, growing gastric cancer screening initiatives and decentralized healthcare services are supporting market penetration across developing regions.
Test Location Insights
Hospital-based testing held the largest share of 39.52% of the market in 2025, primarily due to the high patient inflow, availability of advanced diagnostic infrastructure, and strong presence of specialized gastroenterology departments across hospitals. Hospitals remain the primary healthcare settings for the diagnosis and management of Helicobacter pylori infections, peptic ulcers, gastritis, and gastric cancer-related conditions. The increasing preference for accurate, non-invasive gastrointestinal diagnostic procedures, combined with rising hospitalization rates for digestive disorders, continues to support segment growth. Furthermore, in November 2025, several healthcare institutions across Japan and South Korea expanded hospital-based gastric cancer screening and H. pylori management programs, increasing the adoption of advanced 13C urea breath testing systems for early disease detection and monitoring. The availability of skilled healthcare professionals, integrated laboratory services, and advanced diagnostic technologies within hospital settings further strengthens this segment's dominance in the global market.
Point-of-Care Testing (POCT) is expected to grow at the fastest CAGR over the forecast period, supported by the increasing demand for rapid, non-invasive, and decentralized gastrointestinal diagnostic solutions. The growing adoption of portable 13C urea breath analyzers, rising preference for outpatient and home-based testing, and expanding healthcare access across remote and underserved regions are significantly supporting segment growth. In addition, increasing integration of AI-assisted diagnostic platforms and telehealth-enabled gastrointestinal screening programs improved the accessibility and efficiency of point-of-care Helicobacter pylori testing services. The growing focus on faster clinical decision-making, reduced hospital burden, and early detection of gastrointestinal disease is further accelerating the adoption of POCT-based urea breath testing globally.
Application Insights
The H. pylori initial diagnosis segment accounted for the largest revenue share of 39.05% in 2025, driven by the increasing global prevalence of Helicobacter pylori infections and rising awareness regarding early gastrointestinal disease detection. Urea breath tests are widely preferred for initial diagnosis due to their high sensitivity, non-invasive nature, rapid turnaround time, and ability to accurately identify active infections compared to serology-based methods accurately. The increasing burden of peptic ulcers, chronic gastritis, dyspepsia, and gastric cancer is significantly supporting segment growth. Furthermore, a November 2025 study published in the International Journal of Molecular Sciences reported that East Asian countries such as Japan, China, and South Korea continue to experience a disproportionately high burden of H. pylori-associated diseases and gastric cancer, underscoring the need for region-specific screening, early detection, and diagnostic management strategies. This further accelerates the adoption of urea breath testing for initial diagnosis across hospitals and diagnostic laboratories.
Post-treatment confirmation is expected to grow at the fastest rate over the forecast period, supported by the increasing emphasis on verifying successful Helicobacter pylori eradication following antibiotic therapy. Rising concerns about antibiotic resistance, treatment failure, and recurrent gastrointestinal infections are driving increased demand for accurate follow-up diagnostic testing. Urea breath tests are widely preferred for post-treatment confirmation due to their high accuracy in detecting active infections and their ability to provide reliable non-invasive monitoring. Moreover, a 2025 review published in Gastroenterology highlighted that declining eradication rates and increasing antimicrobial resistance are driving stronger implementation of test-of-cure practices and susceptibility-guided H. pylori management strategies, particularly across high-risk patient populations. This trend is further accelerating the adoption of urea breath testing for post-treatment confirmation across hospitals and gastroenterology clinics globally.
Patient Population Insights
The adults segment accounted for the largest revenue share of 65.70% in 2025. The segment’s growth is primarily driven by the high prevalence of Helicobacter pylori infections, peptic ulcers, chronic gastritis, dyspepsia, and gastric cancer among the adult population. Adults represent the largest patient group undergoing gastrointestinal diagnostic procedures due to increasing lifestyle-related digestive disorders, unhealthy dietary habits, smoking, alcohol consumption, and rising stress levels. Urea breath tests are widely preferred among adult patients because of their high diagnostic accuracy, non-invasive nature, and rapid results. Additionally, a November 2025 study published in the International Journal of Molecular Sciences reported that H. pylori infection continues to affect more than half of the global population, with particularly high prevalence rates among adults across East Asian countries, including Japan, China, and South Korea, significantly increasing the demand for adult gastrointestinal screening and diagnostic testing services globally.
The pediatrics segment is expected to grow at the fastest CAGR during the forecast period, driven by the increasing prevalence of Helicobacter pylori infections and gastrointestinal disorders among children and adolescents. The growing preference for non-invasive, radiation-safe diagnostic methods is significantly accelerating the adoption of 13C urea breath tests in pediatric patient populations. Increasing awareness of early gastrointestinal disease detection, improved pediatric healthcare access, and a rising focus on preventive healthcare are further supporting segment growth. Additionally, the increasing adoption of child-friendly diagnostic technologies and the expanding availability of advanced gastrointestinal testing services across hospitals and diagnostic laboratories are expected to accelerate this segment's global growth further.
Regional Insights
North America urea breath test industry dominated the global market in 2025, accounting for 48.38% share in 2025, driven by advanced healthcare infrastructure, high awareness of gastrointestinal disease diagnosis, and the widespread adoption of non-invasive diagnostic technologies. The region benefits from the increasing prevalence of Helicobacter pylori infections, peptic ulcer disease, chronic gastritis, and gastric cancer-related conditions. Hospitals and diagnostic laboratories across North America are increasingly adopting advanced 13C urea breath-testing systems for their high diagnostic accuracy and rapid turnaround time. Growing emphasis on early disease detection, preventive healthcare, and gastric cancer risk management is further supporting market growth. In addition, favorable reimbursement frameworks, robust gastroenterology research, and increasing adoption of evidence-based H. pylori management guidelines continue to strengthen the regional market landscape.
U.S. Urea Breath Testing Market Trends
The urea breath test industry in the U.S. accounted for the largest share within North America due to the high prevalence of Helicobacter pylori infections and the increasing burden of gastrointestinal disorders among adult populations. The country is witnessing growing adoption of non-invasive gastrointestinal diagnostic procedures across hospitals, gastroenterology clinics, and outpatient diagnostic centers. Increasing awareness regarding early gastric cancer prevention and rising focus on test-of-cure practices following H. Pylori eradication therapy is significantly supporting market growth. Additionally, the availability of advanced diagnostic technologies, skilled healthcare professionals, and strong clinical guideline adoption continues to accelerate the use of urea breath testing nationwide. Rising healthcare expenditure and the growing demand for point-of-care gastrointestinal diagnostics are also driving market expansion in the U.S.
Europe Urea Breath Testing Market Trends
The Europe urea breath test industry is witnessing steady growth driven by increasing awareness of gastrointestinal disease screening and the rising adoption of non-invasive diagnostic technologies across healthcare systems. The growing prevalence of Helicobacter pylori infections, chronic gastritis, dyspepsia, and peptic ulcer disease is significantly driving market demand across the region. Countries across Europe are increasingly focusing on early gastric cancer prevention and improved gastrointestinal disease management through advanced diagnostic testing strategies. The presence of established healthcare infrastructure, strong diagnostic laboratory networks, and increasing investments in point-of-care testing technologies are further supporting market growth. In addition, the rising adoption of personalized treatment approaches and antimicrobial resistance monitoring programs for H. pylori management is accelerating the utilization of accurate post-treatment diagnostic testing across hospitals and specialty gastroenterology centers.
The urea breath test industry in the UK is expanding due to the increasing prevalence of digestive disorders and rising demand for rapid, non-invasive gastrointestinal diagnostic procedures. Healthcare providers across the country are increasingly adopting urea breath testing for the diagnosis and post-treatment confirmation of Helicobacter pylori infections, given its high sensitivity and patient convenience. Growing awareness regarding early gastrointestinal disease detection and rising focus on reducing invasive endoscopic procedures are further supporting market growth. In addition, the increasing burden of antibiotic resistance associated with H. pylori treatment is driving demand for accurate follow-up testing services. Expanding outpatient diagnostic services and growing integration of point-of-care testing technologies across healthcare facilities are also contributing to the increasing adoption of urea breath testing in the UK.
The urea breath test industry in Germany is witnessing significant growth driven by the country’s advanced healthcare infrastructure, a strong diagnostic laboratory network, and an increasing focus on gastrointestinal disease management. The rising prevalence of Helicobacter pylori infections and growing awareness of gastric cancer prevention are driving the adoption of non-invasive diagnostic technologies across hospitals and specialty clinics. Germany is also experiencing increasing demand for rapid, accurate post-treatment confirmation testing due to growing concerns about antimicrobial resistance and treatment failure rates. In addition, the country’s emphasis on technological innovation and precision diagnostics is supporting the adoption of advanced 13C urea breath analyzers and automated gastrointestinal testing platforms. Increasing investments in outpatient care services and point-of-care diagnostics are further driving market expansion nationwide.
Asia Pacific Urea Breath Testing Market Trends
The Asia Pacific urea breath test industry is expected to witness the fastest growth during the forecast period, driven by the high prevalence of Helicobacter pylori infections and the increasing incidence of gastric cancer across the region. Countries across the Asia Pacific continue to experience a substantial burden of gastrointestinal diseases, particularly in densely populated developing economies. Rising healthcare expenditure, improved access to advanced diagnostic technologies, and growing awareness of early disease detection are significantly driving market growth. Governments and healthcare organizations across the region are increasingly focusing on gastric cancer prevention and population-based screening strategies, accelerating the adoption of urea breath testing. Furthermore, expanding healthcare infrastructure, increased availability of point-of-care diagnostic systems, and rising investments in decentralized healthcare services are driving strong market expansion across the Asia Pacific.
The urea breath test industry in China is witnessing rapid growth driven by a large patient population, a high prevalence of Helicobacter pylori infections, and an increasing incidence of gastric cancer. Growing awareness regarding gastrointestinal disease diagnosis and expanding access to healthcare services are significantly supporting market expansion. Hospitals and diagnostic laboratories across China are increasingly adopting non-invasive diagnostic technologies to improve early disease detection and reduce dependence on invasive endoscopic procedures. In addition, rising healthcare investments, improved diagnostic infrastructure, and increased implementation of gastric cancer prevention initiatives are accelerating the use of urea breath testing services. The country is also experiencing growing demand for portable and point-of-care gastrointestinal diagnostic solutions across urban and semi-urban healthcare settings.
The urea breath test industry in Japan is experiencing strong growth due to the country’s high burden of Helicobacter pylori-associated gastric diseases and established focus on early gastric cancer prevention. Japan has one of the most advanced gastrointestinal diagnostic and screening infrastructures globally, supporting widespread adoption of non-invasive diagnostic technologies. Increasing implementation of H. pylori screening, eradication, and post-treatment monitoring strategies is significantly driving demand for urea breath testing across hospitals and gastroenterology centers. In addition, the growing aging population and increasing prevalence of chronic digestive disorders are further supporting market growth. The country’s strong emphasis on technological innovation and precision healthcare is also accelerating the adoption of advanced 13C urea breath testing systems and automated diagnostic platforms.
Latin America Urea Breath Testing Market Trends
Latin America urea breath test industry is witnessing moderate growth due to the increasing prevalence of gastrointestinal disorders and improving awareness regarding Helicobacter pylori infection diagnosis across the region. Rising healthcare investments and the gradual expansion of diagnostic laboratory infrastructure are supporting the adoption of non-invasive gastrointestinal testing technologies. Countries across Latin America continue to experience a substantial burden of peptic ulcer disease, chronic gastritis, and gastric cancer-related conditions, increasing demand for accurate diagnostic solutions. In addition, improving access to healthcare services and growing adoption of outpatient diagnostic testing are contributing to market growth. Increasing focus on preventive healthcare and expansion of point-of-care diagnostic capabilities are also expected to support the utilization of urea breath testing technologies across the region during the forecast period.
Middle East & Africa Urea Breath Testing Market Trends
The Middle East & Africa urea breath test industry is experiencing gradual growth due to the high prevalence of Helicobacter pylori infections and the increasing burden of gastrointestinal diseases across several countries in the region. Improving healthcare infrastructure, rising awareness regarding gastric disease diagnosis, and increasing investments in diagnostic laboratory services are supporting market expansion. The growing demand for non-invasive and cost-effective diagnostic procedures is accelerating the adoption of urea breath testing across hospitals and specialty clinics. In addition, expanding healthcare access and increasing focus on early disease detection are contributing to rising utilization of gastrointestinal diagnostic services. The region is also witnessing growing interest in portable, decentralized diagnostic technologies to improve healthcare access for underserved and remote populations.
Key Urea Breath Testing Company Insights
Key players in the urea breath test industry are primarily focusing on product innovation, expanding non-invasive diagnostic portfolios, and strengthening point-of-care testing capabilities to enhance market competitiveness. Companies are increasingly investing in portable 13C urea breath analyzers, AI-assisted diagnostic platforms, automated reporting systems, and digital healthcare integration to improve diagnostic efficiency and patient accessibility. Strategic collaborations with hospitals, gastroenterology clinics, and diagnostic laboratories are also being adopted to expand global distribution networks and strengthen regional presence. In addition, market participants are emphasizing technological advancements in mass spectrometry, infrared spectroscopy, and rapid gastrointestinal diagnostics to improve testing accuracy, optimize workflows, and enhance post-treatment monitoring capabilities across healthcare settings.
Key Urea Breath Testing Companies:
The following key companies have been profiled for this study on the urea breath testing market.
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories Inc.
Sercon Group
Kibion GmbH
AdvaCare Pharma
Kizlon Inc.
Meridian Bioscience Inc.
Paladin Pharma S.p.a.
Eurofins Scientific
Beijing Richen-Force Science & Technology Co., Ltd
Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd
AESKU.GROUP GmbH
Recent Developments
In January 2026, AIG hospitals introduced PYtest, a non-invasive urea 14C breath test developed by Barry Marshall for the rapid detection of Helicobacter pylori infections. The test provides both qualitative and quantitative results within minutes, without requiring invasive endoscopy procedures, supporting early diagnosis of gastrointestinal disease and expanding the adoption of non-invasive breath-testing technologies across India.
In January 2025, the U.S. Food and Drug Administration approved the PyloPlus UBT system for the detection of Helicobacter pylori infection in patients aged three years and older, supporting the expansion of non-invasive gastrointestinal diagnostic technologies and improving pediatric testing accessibility. The approval further strengthened the adoption of 13C urea breath testing systems across hospitals and diagnostic laboratories by enhancing early diagnosis and post-treatment monitoring capabilities for gastrointestinal disorders.
In March 2025, researchers at Ulm University developed a miniaturized smartphone-compatible breath sensor for rapid Helicobacter pylori detection using 13C-labelled urea analysis. The innovation supported the advancement of portable point-of-care urea breath testing technologies and decentralized gastrointestinal diagnostics. The infrared-based mini-sensor system was designed to provide fast, cost-effective, and non-invasive breath analysis, significantly improving accessibility to early gastrointestinal disease screening and outpatient diagnostic services.
Competitive Benchmarking
Operating Strategies | Competitive Edge | Weaknesses |
Mature Players: Thermo Fisher Scientific Inc. | ||
|
|
|
Emerging Players: Advacare Pharma | ||
|
|
|